Evidence map›Paper›PMID 30401965›Full record

Trial reportBone marrow transplantation2019

Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation.

Hisayuki Yokoyama, Junya Kanda, Shunichi Kato, Eisei Kondo, Yoshinobu Maeda, Hiroo Saji, Satoshi Takahashi, Makoto Onizuka, Yasushi Onishi, Yukiyasu Ozawa and 9 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Assessing the significance of cytomegalovirus reactivation in recipients of allogeneic hematopoietic stem cell transplantation: a cohort study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 1 country.

Hisayuki YokoyamaDepartment of Hematology, Sendai Medical Center, National Hospital Organization, Sendai, Japan. yokoyamah@snh.go.jp.ORCID 0000-0001-7658-0687
Junya KandaDepartment of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-6704-3633
Shunichi KatoDepartment of Cell Transplantation and Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan.
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University, Okayama, Japan.
Hiroo SajiHLA Laboratory, Kyoto, Japan.
Satoshi TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Yasushi OnishiDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Heiwa KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Yuju OhnoDepartment of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Minoko TakanashiBlood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Koji KatoDepartment of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation
Tokai University · JPHiroshima University · JPJichi Medical University · JPKanagawa Prefectural Hospital Organization · JPOkayama University · JPJapanese Red Cross Society, Japan · JPKitakyushu Municipal Medical Center · JPKyoto University · JPNagoya University · JPSendai Medical Center · JPThe University of Tokyo · JPTohoku University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although human leukocyte antigen (HLA) mismatch is often thought to be associated with a high incidence of cytomegalovirus (CMV) reactivation, it is not clear whether this process is mediated by HLA mismatch or other factors, such as acute graft-versus-host disease (aGVHD). Here we focused on cord blood transplantation (CBT) and examined the effects of HLA mismatch on the incidence of CMV reactivation while minimizing the effects of aGVHD. In a multivariate analysis considering aGVHD as a time-dependent covariate, a significant effect on the incidence of CMV reactivation was noted for HLA disparity (hazard ratio [HR]: 0.54 for 8/8 match compared with 3-allele mismatch) and development of aGVHD (HR: 1.26). Next, in an analysis excluding cases that developed aGVHD, the incidences of CMV reactivation for 8/8 match and 1-allele mismatch were low compared with those for other mismatches. These findings were supported by the multivariate analysis (HR: 0.49 for 8/8 match and 0.64 for 1-allele mismatch compared with 3-allele mismatch). Together, these results suggested that HLA mismatch was involved in CMV reactivation and was associated with high morbidity of opportunistic infection after CBT.

Indexed as

AllograftsCytomegalovirus InfectionsGraft vs Host DiseaseVirus ActivationAcute DiseaseAdultCord Blood Stem Cell TransplantationCytomegalovirusFemaleHematologic NeoplasmsHistocompatibility TestingHLA AntigensHumansIncidenceMaleMiddle AgedHLA Antigens

Identifiers

PMID30401965
OpenAlexW2899841553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.